Compare IMOS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMOS | HRMY |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2007 | 2020 |
| Metric | IMOS | HRMY |
|---|---|---|
| Price | $57.64 | $36.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $48.25 |
| AVG Volume (30 Days) | 79.1K | ★ 944.1K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $26.59 | $18.60 |
| Revenue Next Year | $16.41 | $13.25 |
| P/E Ratio | $158.35 | ★ $19.53 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $20.45 | $25.90 |
| 52 Week High | $83.84 | $43.49 |
| Indicator | IMOS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 39.37 |
| Support Level | $53.64 | $35.25 |
| Resistance Level | $59.44 | $39.34 |
| Average True Range (ATR) | 2.45 | 1.68 |
| MACD | -2.32 | -0.23 |
| Stochastic Oscillator | 10.97 | 40.25 |
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.